441 related articles for article (PubMed ID: 32193826)
1. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
[TBL] [Abstract][Full Text] [Related]
2. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
3. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
[TBL] [Abstract][Full Text] [Related]
4. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
[TBL] [Abstract][Full Text] [Related]
5. Effects of dimethyl fumarate on lymphocyte subsets.
Berkovich R; Weiner LP
Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
[TBL] [Abstract][Full Text] [Related]
6. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
7. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
[TBL] [Abstract][Full Text] [Related]
9. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
Nixon R; Bergvall N; Tomic D; Sfikas N; Cutter G; Giovannoni G
Adv Ther; 2014 Nov; 31(11):1134-54. PubMed ID: 25414048
[TBL] [Abstract][Full Text] [Related]
10. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
[TBL] [Abstract][Full Text] [Related]
11. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis.
Wicks P; Rasouliyan L; Katic B; Nafees B; Flood E; Sasané R
BMC Res Notes; 2016 Sep; 9(1):434. PubMed ID: 27604188
[TBL] [Abstract][Full Text] [Related]
12. Lymphocyte recovery after fingolimod discontinuation in patients with MS.
Nagy S; Kuhle J; Derfuss T
Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801166
[TBL] [Abstract][Full Text] [Related]
13. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Zhu C; Kalincik T; Horakova D; Zhou Z; Buzzard K; Skibina O; Alroughani R; Izquierdo G; Eichau S; Kuhle J; Patti F; Grand'Maison F; Hodgkinson S; Grammond P; Lechner-Scott J; Butler E; Prat A; Girard M; Duquette P; Macdonell RAL; Weinstock-Guttman B; Ozakbas S; Slee M; Sa MJ; Van Pesch V; Barnett M; Van Wijmeersch B; Gerlach O; Prevost J; Terzi M; Boz C; Laureys G; Van Hijfte L; Kermode AG; Garber J; Yamout B; Khoury SJ; Merlo D; Monif M; Jokubaitis V; van der Walt A; Butzkueven H;
JAMA Neurol; 2023 Jul; 80(7):739-748. PubMed ID: 37273217
[TBL] [Abstract][Full Text] [Related]
14. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
16. Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate.
Chu L; Balusha A; Casserly C; Berger W; Morrow SA
Mult Scler Relat Disord; 2022 Jan; 57():103384. PubMed ID: 35158477
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
J Neurol; 2021 Mar; 268(3):941-949. PubMed ID: 32974794
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
[TBL] [Abstract][Full Text] [Related]
19. Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.
Tsantes E; Curti E; Ferraro D; Lugaresi A; Baldi E; Montepietra S; Immovilli P; Simone AM; Mancinelli L; Strumia S; Vitetta F; Foschi M; Ferri C; Ferrarini C; Sola P; Granella F
Eur J Neurol; 2021 Jan; 28(1):269-277. PubMed ID: 32931130
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with dimethyl fumarate-induced lymphopenia.
Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
